Clinicopathological evaluation of triple-negative breast cancer treated with keynote-522 regimen
The efficacy of CT + ICI regimen in the real world, although higher than CT, is lower than that observed on the KN 522 clinical trial. Our results need validation in a larger cohort.
Authors
- Kristopher Attwood (ORCID: https://orcid.org/0000-0002-7229-5472)
- Gary Tozbikian (ORCID: https://orcid.org/0000-0002-5941-5652)
- Han Yu (ORCID: https://orcid.org/0000-0001-6160-173X)
- Song Yao (ORCID: https://orcid.org/0000-0001-9442-1313)
- Oluwole Fadare (ORCID: https://orcid.org/0000-0001-8017-2854)
- Briana To
- Dionisia Quiroga (ORCID: https://orcid.org/0000-0003-3388-7069)
- Thaer Khoury (ORCID: https://orcid.org/0000-0002-8112-6590)
- Samira Syed (ORCID: https://orcid.org/0000-0002-4645-7749)
- Yisheng Fang
- Shipra Gandhi
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- UC San Diego Health System (US)
- The Ohio State University Wexner Medical Center (US)
- University of California San Diego (US)
- The Ohio State University (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1093/oncolo/oyaf231
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute